醫(yī)藥衛(wèi)生]霍奇金淋巴瘤的診治進(jìn)展-文庫(kù)吧
2024-12-20 08:57 本頁(yè)面
【正文】 n ABVD ? Stanford V ? MOPPEBVCAD ? VAPECB ? ChlVPP/EVA ? BEACOPP（ escalated） ? The BEACOPP regimen was developed in Germany ? Volker Diehl and colleagues ? be useful for unfavorable, advancedstage Hodgkin39。s lymphoma ? However, escalated BEACOPP is associated with greater hematologic toxicity and a higher incidence of secondary malignancies. ? Bleomycin: 10 mg/m2, day 8 ? Etoposide: 200 mg/m2, days 13 ? Doxorubicin: 35 mg/m2, day 1 ? Cyclophosphamide: 1,250 mg/m2, day 1 ? Vincristine: mg/m2, day 8 ? Procarbazine: 100 mg/m2, days 17 ? Prednisone: 40 mg/m2, days 114 Escalated BEACOPP regimen MEC(MOPP/EBV/CAD) ASH 2022會(huì)議 ? 有關(guān)一些新的治療方案的探索 關(guān)于 NLPHL的 RCHOP治療 ? . Anderson Cancer Center 83例 Blood (ASH Annual Meeting Abstracts) 2022 116: Abstract 2812 E2496: ABVD vs Stanford V 177。 Radiation Therapy in Advanced Hodgkin Lymphoma ? Primary endpoint: failurefree survival Gordon LI, et al. ASH 2022. Abstract 415. ABVD 68 cycles modified IFRT 36 Gy only in patients with massive mediastinal disease (n = 404) Stanford V 12 wks’ chemotherapy, modified IFRT 36 Gy to sites 5 cm in max transverse dimension (n = 408) *Defined as mass ≥ 1/3 maximum intrathoracic diameter on standing PA chest xray. Previously untreated patients with histologically proven HL, advanced or locally extensive disease, massive mediastinal adenopathy* (N = 812) E2496: Results ? ABVD remains standard of care ? 5yr FFS: higher for ABVD ? Similar rates of toxi
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1